Polyrizon Ltd. announced today the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus. These studies utilize the company's proprietary drug delivery platform.
The global acute repetitive seizures market was estimated at USD 3.15 billion in 2024 and is projected to grow at a CAGR of 12.7% from 2025 to 2030. Intranasal delivery of BZDs offers advantages over traditional routes, including ease of use and increased accessibility for rapid administration in out-of-hospital settings.
The studies, conducted in collaboration with Professor Fabio Sonvico of the University of Parma, will assess key parameters such as drug loading capacity, release kinetics, nasal deposition, and stability. This work lays the groundwork for further safety and efficacy testing, aiming to offer a faster, safer, and more accessible solution for managing acute seizures.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.